Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic Hepatitis B, documented by Clinical history compatible with chronic HBV~Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Patient is pregnant or breastfeeding~* Patient is co infected with hepatitis C virus (HCV), hepatitis D virus (HDV), HIV-1 or HIV-2.~* Patient previously received lamivudine or an investigational anti-HBV nucleoside or nucleotide analog at any time~* Patient has received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study~Other protocol defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).